Strand Therapeutics is pioneering programmable mRNA gene therapies. Traditional mRNA therapies simply express encoded proteins inside the body. Strand’s mRNA programming technology can design mRNA capable of entering cells, sensing the cell’s identity, and then execute the appropriate therapeutic program. Their technology, invented at MIT by the founders and advisors, is the first of its kind in the mRNA field and is positioned to leapfrog existing mRNA drugs currently under development in immuno-oncology, cell therapy, immunology, and rare disease.